NeuroBo Pharmaceuticals

Neuro Bo Pharmaceuticals

Pharmaceuticals, 177 Huntington Ave, Boston, Massachusetts, 02116, United States, 1-10 Employees

neurobopharma.com

  • LinkedIn

phone no Phone Number: 85********

Who is NEUROBO PHARMACEUTICALS

NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimers disease. Our Phase III-ready drug, NB-01, is based on natural sources and has shown s...

Read More

map
  • 177 Huntington Ave, Boston, Massachusetts, 02116, United States Headquarters: 177 Huntington Ave, Boston, Massachusetts, 02116, United States
  • 2017 Date Founded: 2017
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies
  • Hyung Kim CEO:   Hyung Kim

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from NEUROBO PHARMACEUTICALS

NeuroBo Pharmaceuticals Org Chart and Mapping

Hyung Kim

Chief Executive Officer

Employees

Nikki Shannon

Vice President, Clinical Operations and Program Management

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding NeuroBo Pharmaceuticals

Answer: NeuroBo Pharmaceuticals's headquarters are located at 177 Huntington Ave, Boston, Massachusetts, 02116, United States

Answer: NeuroBo Pharmaceuticals's phone number is 85********

Answer: NeuroBo Pharmaceuticals's official website is https://neurobopharma.com

Answer: NeuroBo Pharmaceuticals's revenue is $5 Million to $10 Million

Answer: NeuroBo Pharmaceuticals's SIC: 2836

Answer: NeuroBo Pharmaceuticals's NAICS: 541714

Answer: NeuroBo Pharmaceuticals has 1-10 employees

Answer: NeuroBo Pharmaceuticals is in Pharmaceuticals

Answer: NeuroBo Pharmaceuticals contact info: Phone number: 85******** Website: https://neurobopharma.com

Answer: NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimers disease. Our Phase III-ready drug, NB-01, is based on natural sources and has shown successful Phase II results with excellent efficacy and safety in diabetic neuropathic pain (DNP) and we have strong preclinical data in both neuropathic pain and diabetes models showing a mode of action of NB-01 on nerve growth factor (NGF) release for nerve stabilization and regeneration. 40 to 50 percent of patients with diabetic peripheral neuropathy have some form of neuropathic pain and while existing drugs alleviate pain symptoms, they do not address the underlying disease. These current therapies also have a range of adverse effects, and only about 50 percent of patients respond positively. Additionally, the current therapies on the market were all initially approved for other disease states such as depression and fibromyalgia. NB-02, our lead Alzheimers drug, is in IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimers disease (inhibition of AChE, pTau, amyloid-, and stimulation of NGF for nerve growth. An aging population has resulted in an increase in the prevalence of Alzheimers disease, and the disease is a significant healthcare burden. Today, there are four approved drugs that manage the symptoms of Alzheimers disease, yet none of these four address disease modification.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access